[HTML][HTML] MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
D Yan, JM Huelse, D Kireev, Z Tan… - The Journal of …, 2022 - Am Soc Clin Investig
JCI - MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung
cancer Go to JCI Insight About Editors Consulting Editors For authors Publication ethics Alerts …
cancer Go to JCI Insight About Editors Consulting Editors For authors Publication ethics Alerts …
[HTML][HTML] MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
D Yan, JM Huelse, D Kireev, Z Tan, L Chen… - The Journal of …, 2022 - ncbi.nlm.nih.gov
Acquired resistance is inevitable in non–small cell lung cancers (NSCLCs) treated with
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer
D Yan, JM Huelse, D Kireev, Z Tan… - The Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
[HTML][HTML] MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
D Yan, JM Huelse, D Kireev, Z Tan… - The Journal of …, 2022 - Am Soc Clin Investig
Acquired resistance is inevitable in non–small cell lung cancers (NSCLCs) treated with
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
D Yan, JM Huelse, D Kireev, Z Tan, L Chen… - The Journal of …, 2022 - europepmc.org
Acquired resistance is inevitable in non–small cell lung cancers (NSCLCs) treated with
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
D Yan, JM Huelse, D Kireev, Z Tan… - Journal of Clinical …, 2022 - search.proquest.com
Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …
osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 …